Outcomes related to 4864 pregnancies with exposure to lopinavir/ritonavir (LPV/r)

Introduction During pregnancy, LPV/r is a common anchor drug employed to treat the mother's HIV‐1 infection in addition to reducing the risk of mother‐to‐child transmission (MTCT). The National Study of HIV in Pregnancy and Childhood (NSHPC) conducts a comprehensive population‐based surveillanc...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the International AIDS Society 2014-11, Vol.17 (4 Suppl 3), p.19613-n/a
Main Authors: Tookey, Pat, Thorne, Claire, Martinez‐Tristani, Marisol, Norton, Michael, Wyk, Jean
Format: Article
Language:English
Subjects:
Acquired immune deficiency syndrome
AIDS
Antiretroviral agents
Antiretroviral drugs
Drug therapy
HIV
HIV patients
Human immunodeficiency virus
Infants
Infections
Lopinavir
Patient outcomes
Perinatal infection
Pregnancy
Pregnant women
Ritonavir
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction During pregnancy, LPV/r is a common anchor drug employed to treat the mother's HIV‐1 infection in addition to reducing the risk of mother‐to‐child transmission (MTCT). The National Study of HIV in Pregnancy and Childhood (NSHPC) conducts a comprehensive population‐based surveillance of HIV infection in pregnant women exposed to antiretroviral therapy (ART) in the UK and Ireland; in 2003–2012 over a third of pregnancies reported to the NSHPC involved exposure to LPV/r. Methods We undertook a retrospective were descriptive analysis of individual NSHPC patient data, using pregnancy as the unit of observation. Clinical outcomes for pregnancies reported by June 2013, where women were exposed to LPV/r and due to deliver between January 2003 and December 2012, are described. Results A total of 4864 LPV/r exposed pregnancies in 4118 women were identified. These resulted in 4702 deliveries with 4759 live and 46 stillborn infants. Seventy five percent of women were born in sub‐Saharan Africa, 13% in the UK or Ireland. Median maternal age at conception was 30 years. Nine hundred and eighty (20%) pregnancies were conceived while taking LPV/r, with a median duration of LPV/r exposure of 270 days. A total of 3884 (80%) pregnancies initiated LPV/r after conception, with a median duration of LPV/r exposure of 107 days. Viral load (VL) close to delivery was available for 4083/4702 (87%) deliveries, with VL
ISSN:1758-2652
1758-2652
DOI:10.7448/IAS.17.4.19613